📣 VC round data is live. Check it out!
- Public Comps
- Snibe
Snibe Valuation Multiples
Discover revenue and EBITDA valuation multiples for Snibe and similar public comparables like Renishaw, Bausch + Lomb, Andon Health, Convatec Group and more.
Snibe Overview
About Snibe
Shenzhen New Industries Biomedical Engineering Co Ltd is researching, developing, producing, and selling a series of fully automatic chemiluminescence immunoassay instruments and supporting reagents.
Founded
1995
HQ

Employees
2.8K
Website
Financials (LTM)
EV
$5B
Valuation Multiples
Start free trialSnibe Financials
Snibe reported last 12-month revenue of $706M and EBITDA of $311M.
In the same LTM period, Snibe generated $491M in gross profit, $311M in EBITDA, and $252M in net income.
Revenue (LTM)
Snibe P&L
In the most recent fiscal year, Snibe reported revenue of $677M and EBITDA of $304M.
Snibe is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 45%, and net margin of 35%.
Financial data powered by Morningstar, Inc.
Snibe Stock Performance
Snibe has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Snibe's stock price is $6.68.
Snibe share price decreased by 3.2% in the last 30 days, and by 18.9% in the last year.
Snibe has an EPS (earnings per share) of $0.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | -3.0% | -3.2% | -7.2% | -18.9% | $0.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSnibe Valuation Multiples
Snibe trades at 6.9x EV/Revenue multiple, and 15.7x EV/EBITDA.
EV / Revenue (LTM)
Snibe Financial Valuation Multiples
As of June 3, 2026, Snibe has market cap of $5B and EV of $5B.
Snibe has a P/E ratio of 20.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Snibe Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Snibe Margins & Growth Rates
Snibe grew revenue by 12% and EBITDA by 10% in the last fiscal year.
In the most recent fiscal year, Snibe reported gross margin of 69%, EBITDA margin of 45%, and net margin of 35%.
Snibe Margins
Snibe Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Snibe Operational KPIs
Snibe's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Snibe's Rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Snibe's Rule of X is 74% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Snibe Competitors
Snibe competitors include Renishaw, Bausch + Lomb, Andon Health, Convatec Group, Getinge, Hamamatsu Photonics, Teleflex, Sysmex, Ypsomed and Hangzhou Tigermed.
Most Snibe public comparables operate across Laboratory Services, Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.1x | 4.7x | 22.8x | 20.8x | |||
| 2.0x | 1.9x | 11.4x | 10.7x | |||
| 25.2x | - | 12.7x | - | |||
| 2.7x | 2.6x | 10.1x | 9.8x | |||
| 1.6x | 1.6x | 8.6x | 8.6x | |||
| 3.6x | 3.5x | 17.8x | 17.7x | |||
| 4.0x | 3.7x | 13.0x | 13.1x | |||
| 1.7x | 1.7x | 7.2x | 8.6x | |||
This data is available for Pro users. Sign up to see all Snibe competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Snibe
| When was Snibe founded? | Snibe was founded in 1995. |
| Where is Snibe headquartered? | Snibe is headquartered in China. |
| How many employees does Snibe have? | As of today, Snibe has over 2K employees. |
| Is Snibe publicly listed? | Yes, Snibe is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Snibe? | Snibe trades under 300832 ticker. |
| When did Snibe go public? | Snibe went public in 2020. |
| Who are competitors of Snibe? | Snibe main competitors include Renishaw, Bausch + Lomb, Andon Health, Convatec Group, Getinge, Hamamatsu Photonics, Teleflex, Sysmex, Ypsomed, Hangzhou Tigermed. |
| What is the current market cap of Snibe? | Snibe's current market cap is $5B. |
| What is the current revenue of Snibe? | Snibe's last 12 months revenue is $706M. |
| What is the current revenue growth of Snibe? | Snibe revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Snibe? | Current revenue multiple of Snibe is 6.9x. |
| What is the current EBITDA of Snibe? | Snibe's last 12 months EBITDA is $311M. |
| What is Snibe's EBITDA margin? | Snibe's last 12 months EBITDA margin is 44%. |
| What is the current EV/EBITDA multiple of Snibe? | Current EBITDA multiple of Snibe is 15.7x. |
| What is the current FCF of Snibe? | Snibe's last 12 months FCF is $280M. |
| What is Snibe's FCF margin? | Snibe's last 12 months FCF margin is 40%. |
| What is the current EV/FCF multiple of Snibe? | Current FCF multiple of Snibe is 17.5x. |
| How many companies Snibe has acquired to date? | Snibe hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Snibe has invested to date? | Snibe hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Snibe
Lists including Snibe
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.